Vaccinations have been completed and Valneva expects VALOR trial outcomes to be announced in the first half of 2026, followed by regulatory submissions as planned. Pfizer aims to submit a Biologics ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

Pfizer (PFE) has reportedly decided to sell its entire remaining stake in BioNTech (BNTX), showing a lack of confidence in ...

A wave of lawsuits with novel strategies show that the search for Covid vengeance — and jury awards — has gained force under ...

Bankers and underwriters have plenty to be thankful for. Bond issuance is running hot, this year’s IPO count is up (at least ...

Nirsevimab is a long-acting monoclonal antibody that provides season-long protection against RSV in infants, reducing ...

Despite undertaking a capital increase that raised 27.4 million euros, the company's financial foundation continues to weaken. Shareholders' equity has now dwindled to just 150.5 million euros, ...

AGC Biologics today announced it is partnering with Repair Biotechnologies to tackle one of the world's most persistent health challenges and cause of mortality. The collaboration will focus on ...

Pharmaceutical giant Merck announced the cancellation of a planned $1.3 billion research center in London and the termination ...

The Standing Committee of CITES, an international body responsible for monitoring trade in animal species, announced the results of its review of animal breeding practices in Cambodia, thanking ...

A significant development emerged on November 13 when Pfizer announced it had sold 54.7% of its stake in BioNTech, retaining only $163.5 million worth of shares. This move marks a substantial shift in ...

Today in History for Nov. 19: In 1794, the United States and Britain signed the "Jay Treaty" concerning trade boundaries and commerce.